Home Newsfeeds Maxim Group Downgrades Biotricity to Hold

Maxim Group Downgrades Biotricity to Hold

Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.

byBenzinga Newsdesk

July 15, 2022

1 minute read

Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.

Piper Sandler Maintains Neutral on Fortinet, Raises Price Target to $64

By Benzinga Newsdesk

February 8, 8:18 AM

Piper Sandler analyst Rob Owens maintains Fortinet (NASDAQ:FTNT) with a Neutral and raises the price target from $57 to $64.

FTNT

Evercore ISI Group Downgrades American Electric Power to In-Line, Raises Price Target to $102

By Benzinga Newsdesk

January 24, 8:29 AM

Evercore ISI Group analyst Durgesh Chopra downgrades American Electric Power (NASDAQ:AEP) from Outperform to In-Line and raises the price target from $100 to $102.

AEP

ECS, An ASGN Brand, Named A Prime Contractor On A 10-Year, $60.7B Indefinite Delivery/indefinite Quality Contract From The Department Of Veterans Affairs Office Of Information And Technology

By Benzinga Newsdesk

November 20, 2:42 PM

Company expands its support of digital transformation efforts across VA under new contract vehicleECS, a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE:ASGN) brand, has been named a

ASGN

KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma, Co-investor Thomas Eldered to Serve as Frontier’s Executive Chairman

By Benzinga Newsdesk

October 16, 3:22 AM

KKR, a leading global investment firm, today announced, in partnership with Flerie, the formation of a new global pharma services platform, Frontier Biosolutions ("Frontier"), which will invest in a portfolio

KKR

Maxim Group Downgrades Biotricity to Hold

Related Posts

Piper Sandler Maintains Neutral on Fortinet, Raises Price Target to $64

Evercore ISI Group Downgrades American Electric Power to In-Line, Raises Price Target to $102

ECS, An ASGN Brand, Named A Prime Contractor On A 10-Year, $60.7B Indefinite Delivery/indefinite Quality Contract From The Department Of Veterans Affairs Office Of Information And Technology

KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma, Co-investor Thomas Eldered to Serve as Frontier’s Executive Chairman